Pfizer, a major American pharmaceutical company, found that the effectiveness of preventing the onset was 95.6% in clinical trials to confirm the effect of additional vaccination with the new coronavirus vaccine.
Pfizer is conducting a clinical trial to see if the effect of the vaccine will decrease with time after the inoculation and whether the effect will increase again with the third inoculation, and announced the result on the 21st.
In clinical trials, about 10,000 people were divided into half, and the number of people who developed the new coronavirus infection in the group who was vaccinated as the third vaccination and the group who was vaccinated with a fake drug called placebo was compared. I did.
As a result, 7 days after vaccination, the new coronavirus infection occurred in 5 patients in the vaccinated group, compared with 109 patients in the placebo vaccinated group.
For this reason, Pfizer states that the effectiveness of preventing the onset of the third inoculation was 95.6%, "we were able to return to the level after the second inoculation."
In the United States, the third dose of Pfizer vaccine has been started last month for people aged 65 and over and those at high risk of aggravation, and the CDC = disease will soon be given to the Moderna and Johnson End Johnson vaccines. The Centers for Disease Control is expected to make the final decision on additional vaccinations.